Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2023-09-15 00:00:00 ET · period of report 2023-09-13 · accession 0000950170-23-048440 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-15 | 2023-09-13 | SPRO | HAMED KAMAL | Chief Medical Off | S - Sale | $1.27 | -39.5K | 576.5K | -6% | -$50.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-13 | S | D | 39,496 | $1.27 | 576,461 | D | — | — | (F2) The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.27 to $1.295 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |